RareStone Group products

WAKIX® is a narcolepsy treatment that Citrine has in-licensed from the French biotech company, Bioprojet, for use in China. WAKIX®(Pitolisant) is the first-in-class novel mechanism H3 receptor antagonist approved by the European Medicines Agency (EMA) in 2016 and by FDA in 2018. It will be the first approved medicine for narcolepsy treatment in China. In the mean time, it has the potential to expand its indication to the treatment of pediatric narcoleptic patients with or without cataplexy and obstructive sleep apnea syndrome.

WAKIX^® (pitolisant) is a narcolepsy treatment that Citrine has in-licensed from the French biotech company, Bioprojet, for use in China. Pitolisant is a selective histamine H3-receptor antagonist/inverse agonist, which increases the release of the brain chemical histamine to increase a patient`s wakefulness and alertness. The drug was approved by the European Medicines Agency (EMA) in 2016 for the treatment of narcolepsy in adults with or with0out cataplexy and is marketed in major countries in Europe. It was approved by the FDA in 2018 to treat adults suffering from narcolepsy, a serious, chronic disorder characterized by excessive daytime sleepiness (EDS), with or without cataplexy.